Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine

被引：0
|
作者：
Anne Luise Haulund Vollesen
Faisal Mohammad Amin
Messoud Ashina
机构：
[1] University of Copenhagen,Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences
来源：
Neurotherapeutics | 2018年 / 15卷
关键词：
PACAP38; PAC; receptor; Vasoactive intestinal polypeptide; Human provocation models; Primary headaches; Migraine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Here, we review the role of pituitary adenylate cyclase-activating peptide-38 (PACAP38) in migraine pathophysiology and data implicating PAC1 receptor as a future drug target in migraine. Much remains to be fully elucidated about migraine pathophysiology, but recent attention has focused on signaling molecule PACAP38, a vasodilator able to induce migraine attacks in patients who experience migraine without aura. PACAP38, with marked and sustained effect, dilates extracerebral arteries but not the middle cerebral artery. The selective affinity of PACAP38 to the PAC1 receptor makes this receptor a highly interesting and potential novel target for migraine treatment. Efficacy of antagonism of this receptor should be investigated in randomized clinical trials.
引用
收藏
页码：371 / 376
页数：5
相关论文
共 50 条
  • [1] Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine
    Vollesen, Anne Luise Haulund
    Amin, Faisal Mohammad
    Ashina, Messoud
    NEUROTHERAPEUTICS, 2018, 15 (02) : 371 - 376
  • [2] The Role of Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide in Migraine Pathogenesis
    Sokolov, A. Y.
    Osipchuk, A. V.
    Skiba, I. B.
    Amelin, A. V.
    NEUROCHEMICAL JOURNAL, 2022, 16 (01) : 31 - 38
  • [3] The Role of Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide in Migraine Pathogenesis
    A. Y. Sokolov
    A. V. Osipchuk
    I. B. Skiba
    A. V. Amelin
    Neurochemical Journal, 2022, 16 : 31 - 38
  • [4] Role of Pituitary Adenylate Cyclase-Activating Polypeptide in Nociception and Migraine
    Tajti, Janos
    Tuka, Bernadett
    Botz, Balint
    Helyes, Zsuzsanna
    Vecsei, Laszlo
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2015, 14 (04) : 540 - 553
  • [5] Pituitary adenylate cyclase-activating peptide inhibits neutrophil chemotaxis
    Kinhult, J
    Uddman, R
    Laan, M
    Lindén, A
    Cardell, LO
    PEPTIDES, 2001, 22 (12) : 2151 - 2154
  • [6] RECEPTORS FOR PITUITARY ADENYLATE CYCLASE-ACTIVATING PEPTIDE IN HUMAN LIVER
    GUIJARRO, LG
    RODRIGUEZHENCHE, N
    GARCIALOPEZ, E
    NOGUERALES, F
    DAPENA, MA
    JUARRANZ, MG
    PRIETO, JC
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (08): : 2451 - 2457
  • [7] Pituitary adenylate cyclase-activating polypeptide
    Gonzalez, BJ
    Basille, M
    Vaudry, D
    Fournier, A
    Vaudry, H
    ANNALES D ENDOCRINOLOGIE, 1998, 59 (05) : 364 - 405
  • [8] Calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in migraine treatment
    Dominguez-Moreno, Rogelio
    Do, Thien Phu
    Ashina, Messoud
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2022, 29 (02) : 225 - 231
  • [9] Pituitary adenylate cyclase-activating polypeptide
    Li, XL
    Zhao, XX
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2001, 28 (02) : 140 - 144
  • [10] Targeting enkephalins and pituitary adenylate cyclase-activating polypeptide (PACAP) in migraine
    Ashina, Messoud
    BRAIN, 2022, 145 (08) : 2619 - 2620
12345